Gilead Sciences Pharmaceuticals shares jumped 16% after the market closed, the day before yesterday, following a media report that provided encouraging partial data from experiments with the American company's experimental drug "Remdisever" on patients with severe cases of the emerging coronavirus. The (Stat) medical news website reported that a University of Chicago hospital is participating in a study of antivirals, and said it was monitoring a rapid recovery from symptoms of fever and respiratory system, with almost all patients leaving the hospital in less than a week. In the same context, the German "Paul Ehrlich" Institute for Vaccines and Biomedicines expects to soon begin clinical tests for one of the candidate vaccines for combating the virus in Germany. Yesterday, the head of the institute, Klaus Seekotech, said in Berlin that he was sure that there would be tests for other vaccines this year in Germany.